Unicycive Therapeutics, Inc., a biotechnology company headquartered in Los Altos, United States, has been making strides in the healthcare sector with its focus on developing innovative therapies. The company is primarily engaged in the research and development of two novel treatments aimed at addressing hyperphosphatemia, a condition characterized by elevated phosphate levels in the blood, which is commonly associated with chronic kidney disease (CKD) and acute kidney injury (AKI).
As of November 27, 2025, Unicycive Therapeutics’ stock was trading at a close price of $6.47 on the Nasdaq exchange. The company’s market capitalization stood at approximately $139.05 million, reflecting its valuation in the biotechnology sector. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $11 on June 8, 2025, and a 52-week low of $3.71 on September 24, 2025.
The company’s financial metrics indicate a price-to-earnings (P/E) ratio of -2.52, suggesting that it is not currently generating profits. This is not uncommon for biotechnology firms, particularly those in the development phase of their pipeline, as substantial investments are often required for research, clinical trials, and regulatory approvals.
Unicycive Therapeutics’ strategic focus on hyperphosphatemia is driven by the significant unmet medical need in patients suffering from CKD and AKI. Hyperphosphatemia can lead to severe complications, including cardiovascular disease and bone disorders, making effective management crucial for improving patient outcomes. The company’s commitment to advancing its therapeutic candidates underscores its potential to make a meaningful impact in the treatment landscape for these conditions.
As Unicycive Therapeutics continues to progress through its development pipeline, stakeholders are closely monitoring its clinical trial results and regulatory milestones. The company’s ability to successfully bring its therapies to market could position it as a key player in the nephrology space, addressing a critical need for patients with kidney-related disorders.
